NodThera, a UK and US based clinical stage biotechnology company developing a new class of medicines to treat diseases driven by chronic inflammation, raised $55m (£44m) in Series B financing.
Novo Ventures led the round which also included new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, Epidarex Capital, F-Prime Capital and Sofinnova Partners. In conjunction with the funding, Nanna Lüneborg, Partner at Novo Ventures, will join the NodThera board.
Led by Adam Keeney, President and Chief Executive Officer, NodThera is focusing on a new class of anti-inflammatory targets, the NLRP3 inflammasome. In preclinical studies, NT-0167 demonstrated potent and selective inhibition of the NLRP3 inflammasome resulting in reductions of IL-1β and IL-18, pro-inflammatory cytokines which are known to play a key role in chronic inflammation underlying a wide range of diseases.
The financing will support the advancement of NodThera’s pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of lead candidate NT-0167 through clinical development and further progress the development of additional compounds — including brain-penetrant NLRP3 inflammasome inhibitors for central nervous system indications — and continued drug discovery efforts. NodThera maintains offices in Cambridge, UK, Seattle, WA and Boston, MA.